Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2858 in Advanced Malignancies
NCT05154630Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bemosesuglimab in cancer, soft tissue sarcoma (STS), alveolar soft part sarcoma (ASPS), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jan 2022; status: terminated.
02
Drugs
bemosesuglimab
03
Conditions
cancersoft tissue sarcoma (STS)alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on NCT05154630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05154630.